New drug cocktail targets rare spleen cancer in early trial

NCT ID NCT07165769

Recruiting now Disease control Sponsor: Institute of Hematology & Blood Diseases Hospital, China Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 30 times

Summary

This study tests a combination of three drugs (zanubrutinib, obinutuzumab, and lenalidomide) in people newly diagnosed with a rare type of spleen lymphoma called SBLPN. The goal is to see how well the treatment shrinks or controls the cancer and to check for side effects. About 47 adults aged 18 to 80 who have not had prior treatment for this lymphoma will take part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SPLENIC B-CELL LYMPHOMA/LEUKAEMIA WITH PROMINENT NUCLEOLI，SBLPN are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Institute of Hematology and Blood Diseases Hospital ,Chinese Academy of Medical Sciences
RECRUITING

Tianjin, Tianjin Municipality, 300020, China

Contact

Conditions

Explore the condition pages connected to this study.

SPLENIC B-CELL LYMPHOMA/LEUKAEMIA WITH PROMINENT NUCLEOLI，SBLPN